Rising COVID-19 cases are driving up the use of therapeutics, with Pfizer Inc.’s oral antiviral treatment Paxlovid seeing a 315 percent jump over the past four weeks, U.S. health officials said on May 17.
President Joe Biden on May 12 commemorated the death of 1 million people in the United States from COVID-19, marking what he called “a tragic milestone” and urging Americans to “remain vigilant” amid the ongoing pandemic.
World Health Organization states will consider a resolution against Russia next week after its invasion of Ukraine, including the possible closure of a major regional office in Moscow, a document obtained by Reuters showed on May 5.
Protesters rallied under the slogan “off our bodies” in cities across the United States on May 3, demanding abortion rights be protected after the leak of a draft Supreme Court opinion that would overturn the landmark 1973 Roe v. Wade decision.
A World Health Organization spokesperson on May 3 confirmed that its European region would hold a special meeting next week on the impact of Russia’s invasion of Ukraine on health and healthcare.
A planned funding overhaul aimed at strengthening the World Health Organization (WHO) has been partly watered down, according to an internal document seen by Reuters, after pressure from the United States and other donor countries.
Although research is being conducted on Long COVID or Long COVID-19, whose symptoms continue for weeks and months after initial infection, there are very few ongoing clinical trials on treatments. Anecdotally, there has been what appears to be a successful treatment for Long Covid using Pfizer’s antiviral regimen Paxlovid.
Global COVID-19 cases surpassed 500 million on April 14, according to a Reuters tally, as the highly contagious BA.2 sub-variant of Omicron surges in many countries in Europe and Asia.
Coronavirus infections in Asia passed 100 million on March 30, according to a Reuters tally, as the region records a resurgence in cases dominated by the BA.2 Omicron sub-variant.
Medicago’s COVID-19 vaccine – approved during February in Canada – is facing limited growth in the near term after the World Health Organization said it would not review the vaccine because the company is partly owned by U.S.-Swiss tobacco company Philip Morris, health experts say.